) shares continue to inch up since the company announced its new
drug submission (NDS) to Health Canada for its investigational
hepatitis C virus (HCV) infection therapy. Shares were up 0.7%
following the company's announcement. Overall shares increased 1.3%
since the announcement.
AbbVie's oral investigational regimen comprises a fixed-dose
combination of ABT-450/Norvir (150 mg/100 mg) co-formulated with
ABT-267 (once daily) and ABT-333 with or without ribavirin (RBV),
administered twice daily. The company is the looking to get the
combination therapy approved for use in adults with chronic
genotype 1 (GT 1) HCV infection.
The company is developing ABT-450 in collaboration with
). The investigational HCV therapy is also under FDA review for the
We note that on May 1, 2014, Health Canada granted priority review
status to AbbVie's investigational direct-acting antiviral (DAA)
regimen (with and without ribavirin) for the treatment of HCV GT 1.
The designation should help expedite the review process for the
The candidate also has Breakthrough Therapy status in the U.S.
AbbVie intends to commercialize the combination therapy in the U.S.
in late 2014, if approved, and expects EU approval in early 2015.
We are pleased to see AbbVie working on strengthening its HCV
pipeline. However, the market is highly crowded and is led by
). Gilead's Sovaldi (launched in Dec 2013) generated revenues of
$2.27 billion in the first quarter of 2014. Moreover, the company
is looking to get a combination therapy of ledipasvir and Sovaldi
approved in the U.S. and EU.
Johnson & Johnson
) Olysio received approval in the EU for the treatment of genotype
1 and 4 chronic HCV infection.
AbbVie carries a Zacks Rank #3 (Hold). Gilead is a better-ranked
stock with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ABBVIE INC (ABBV): Free Stock Analysis Report
ENANTA PHARMA (ENTA): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
JOHNSON & JOHNS (JNJ): Free Stock Analysis
To read this article on Zacks.com click here.